The short answer
A short study of one standardized ginkgo leaf extract found no meaningful change in rivaroxaban levels or its measured anticoagulant effect. That does not establish safety for every ginkgo product or for long-term use. Discuss the exact supplement with your pharmacist before combining it with rivaroxaban.
What this answer covers
Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- rivaroxaban
What did the direct study find?
Researchers studied 41 evaluable healthy adults taking a single 20 mg rivaroxaban dose, first alone and then during eight days of a standardized ginkgo leaf extract. Rivaroxaban exposure and its anti-factor Xa effect were essentially unchanged. No bleeding-related events were observed, but a short study of this size cannot exclude uncommon bleeding in patients using anticoagulation for months or years.
Which ginkgo product was tested?
The study used EGb 761 at 240 mg daily, a leaf extract with a defined composition. It did not test every supplement sold as ginkgo, ginkgo seeds, higher doses or combination products. The extract was taken one hour before rivaroxaban. Because researchers did not compare different spacing schedules, that detail does not establish a protective one-hour gap. The study was funded by the extract manufacturer.
Why is there still a bleeding precaution?
Rivaroxaban itself can cause serious bleeding. NIH also advises caution with ginkgo in people taking anticoagulants. These broader precautions remain relevant when the product, dose or patient differs from the trial. At the same time, the direct neutral study should not be ignored: it argues against presenting increased rivaroxaban exposure or anticoagulant activity as a proven effect of the tested extract.
What should I discuss with my pharmacist?
Bring the ginkgo label, daily amount and any other supplements to a medication review. Kidney function, bleeding history and medicines such as aspirin can change the overall assessment. Do not stop rivaroxaban or alter its dose to accommodate a supplement. Report unusual bleeding promptly, and seek urgent care for severe or persistent bleeding. The available study offers narrow reassurance, not a personal safety clearance.
Evidence and practical considerations
Side effects & toxicity
A short study of one standardized ginkgo leaf extract found no meaningful change in rivaroxaban levels or its measured anticoagulant effect. That does not establish safety for every ginkgo product or for long-term use. Discuss the exact supplement with your pharmacist before combining it with rivaroxaban.
- Exact scope
- Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses. with adult oral rivaroxaban tablets
- Medication form and route
- adult oral rivaroxaban tablets; oral supplement
- Timing or duration
- Direct comparison: single-dose rivaroxaban alone and during the first and eighth days of daily EGb 761. Longer exposure and chronic clinical outcomes were not established.
What remains uncertain
- A neutral eight-day study of one standardized preparation cannot resolve rare or longer-term clinical bleeding risk across all ginkgo products. General anticoagulant warnings do not establish an exact-pair risk size.
Factors that may matter: Exact supplement formulation, composition and daily dose; Kidney function, indication, bleeding history and concurrent medicines; Recent supplement initiation or discontinuation.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using oral rivaroxaban for approved indications.
Avoid combined P-gp/strong CYP3A inducers including St. John’s wort. Rivaroxaban can cause serious bleeding, and premature discontinuation increases thrombotic risk. Adult 15 mg and 20 mg doses are taken with food.
How this applies: Exact rivaroxaban ingredient and oral formulation. Direct named applicability to Hypericum perforatum avoidance; medication-only context for ginkgo and vitamin E. Exact article scope: Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
General bleeding precautions are not proof that every supplement increases rivaroxaban bleeding. The label does not supply a ginkgo- or vitamin E-specific effect size or safe spacing interval.
Source 2: peer-reviewed prospective human pharmacokinetic and pharmacodynamic study
europepmc.org · Source check Sep 10, 2026
Population: 42 healthy adults enrolled; 41 evaluable participants aged 21-70 years, including 25 men and 16 women.
Repeated-extract rivaroxaban AUC ratio was 97.82% (90% CI 93.73-102.08); anti-Xa effect AUC ratio was 99.12% (93.25-105.35). All primary comparison confidence intervals met the prespecified 80-125% range; no hemorrhage-related events were observed.
How this applies: Direct neutral exposure and anti-Xa evidence for this exact standardized oral ginkgo leaf extract with adult oral rivaroxaban. It does not establish that every ginkgo preparation is harmless, nor that an hourly separation is protective. Exact article scope: Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
Short, open-label, fixed-sequence study of one extract with single-dose rivaroxaban in healthy volunteers; not powered for rare or long-term bleeding. Manufacturer sponsored; three authors were manufacturer employees and the fourth worked for the paid research contractor. No comparison of simultaneous versus one-hour-separated dosing.
Source 3: government botanical safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering ginkgo supplements, including those taking anticoagulants.
NIH cautions about bleeding risk with anticoagulants and advises discussing supplement use with a clinician.
How this applies: Indirect supplement evidence. This source does not establish the size or causality of a rivaroxaban-specific bleeding interaction. Exact article scope: Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
General anticoagulant precaution, not an exact-rivaroxaban trial. It must be weighed against the directly inspected neutral EGb 761 study without assuming all ginkgo products are equivalent.
Research assessment: · Open full citations ↗
Absorption & effectiveness
EGb 761 at 240 mg daily did not meaningfully alter single-dose rivaroxaban exposure or anti-factor Xa activity during an eight-day study in healthy adults. This neutral finding applies to the studied preparation and conditions.
- Exact scope
- Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses. with adult oral rivaroxaban tablets
- Medication form and route
- adult oral rivaroxaban tablets; oral supplement
- Timing or duration
- Direct comparison: single-dose rivaroxaban alone and during the first and eighth days of daily EGb 761. Longer exposure and chronic clinical outcomes were not established.
What remains uncertain
- A neutral pharmacokinetic/pharmacodynamic result in healthy volunteers does not establish long-term clinical safety, equivalence of all ginkgo products, or a protective one-hour interval.
Factors that may matter: Exact supplement formulation, composition and daily dose; Kidney function, indication, bleeding history and concurrent medicines; Recent supplement initiation or discontinuation.
Read the supporting source summaries
Source 1: peer-reviewed prospective human pharmacokinetic and pharmacodynamic study
europepmc.org · Source check Sep 10, 2026
Population: 42 healthy adults enrolled; 41 evaluable participants aged 21-70 years, including 25 men and 16 women.
Repeated-extract rivaroxaban AUC ratio was 97.82% (90% CI 93.73-102.08); anti-Xa effect AUC ratio was 99.12% (93.25-105.35). All primary comparison confidence intervals met the prespecified 80-125% range; no hemorrhage-related events were observed.
How this applies: Direct neutral exposure and anti-Xa evidence for this exact standardized oral ginkgo leaf extract with adult oral rivaroxaban. It does not establish that every ginkgo preparation is harmless, nor that an hourly separation is protective. Exact article scope: Adult oral rivaroxaban and oral Ginkgo biloba leaf products. Direct research applies to EGb 761 at 240 mg/day, not all extracts, seeds, mixtures or doses.
Short, open-label, fixed-sequence study of one extract with single-dose rivaroxaban in healthy volunteers; not powered for rare or long-term bleeding. Manufacturer sponsored; three authors were manufacturer employees and the fourth worked for the paid research contractor. No comparison of simultaneous versus one-hour-separated dosing.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current prescribing information and targeted original sources assessed; current claims adjudicated individually and consumer article written. Exact preparations, conflicting or indirect findings and unresolved limits retained. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 89c6fcc2d57d6063
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.